A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase IV
Latest Information Update: 03 May 2017
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 29 Mar 2017 Status changed from recruiting to completed.
- 07 Mar 2017 This trial has been completed in Poland (end date: 2016-11-16), according to European Clinical Database record.
- 28 Jan 2017 This trial was completed in Hungary, according to European Clinical Database.